Multiple Sclerosis (MS) Franchise Highlights
TECFIDERA (dimethyl fumarate)
The U.S. Food and Drug Administration’s (FDA) approved TECFIDERA on March 27, 2013, as a new first-line oral treatment for people living with relapsing forms of MS, and we launched in the U.S. in early April 2013.
TECFIDERA recently received product approval in Australia from the Therapeutic Goods Administration (TGA) and approval in Canada from Health Canada.On May 29, 2013, Biogen Idec announced it was granted a European patent that extends until 2028 and covers the expected EU TECFIDERA label dose of 480 mg. The Company also announced an expected delay to the launch of TECFIDERA in the EU as it continues to work to make TECFIDERA regulatory data protection clearer to all parties prior to approval from the European Medicines Agency (EMA). TYSABRI (natalizumab) On April 2, 2013, Biogen Idec completed its acquisition of full ownership of, and strategic, commercial and decision-making rights to, TYSABRI from Elan Pharma International, Ltd., an affiliate of Elan Corporation. In June 2013, Biogen Idec submitted a Biologics License Application (BLA) for the marketing approval of TYSABRI with the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. Based on the filing’s priority review, the Company is planning for potential marketing and pricing approval, and anticipated commercial launch of TYSABRI in Japan in 2014. During the second quarter, Biogen Idec also completed enrollment of ASCEND, an important clinical trial using TYSABRI designed to help address a critical unmet need in secondary progressive multiple sclerosis (SPMS). SPMS represents a significant portion of the total MS patient population and there are currently no effective therapies. Data are expected in 2015. Recently, the FDA and EMA approved the manufacture of TYSABRI at our large-scale manufacturing facility in Hillerød, Demark. The site is now a licensed manufacturing facility capable of producing TYSABRI for patients who live outside the United States. The site will also act as a back-up to our Research Triangle Park manufacturing facility in North Carolina for supply of TYSABRI.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV